Browse Studies — Arctuva

Phase 3

A Phase 3 Open-Label, Randomized Controlled Trial of T-bren (BL M07D1) vs. Platinum-based Chemotherapy in Patients With HER2 Expressing Metastatic Urothelial Cancer With Disease Progression on or After Anti-PD-(L)1-based Therapy

The objective of the study is to evaluate the efficacy and safety of T-bren in participants with HER2 expressing metastatic UC with progression on or after ant…

Urothelial CancerMetastatic Urothelial CancerBladder Cancer+9 more

Estimated

~$50 – $2,100

Actual pay is set by the research site.

SystImmune Inc.NCT07869836

Phase 1

A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-501 Administered Intravesically in Adult Participants With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

This study is being conducted to evaluate the safety and tolerability of UGN-501 administered intravesically in adult participants with recurrent non-muscle in…

Bladder (Urothelial, Transitional Cell) CancerNMIBCUrothelial Carcinoma Bladder+5 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.

uTRACT Jelmyto Registry: A Multicenter, Prospective and Retrospective Registry to Evaluate Real World Experience and Outcomes of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in th…

Urothelial CarcinomaUrothelial Carcinoma RecurrentUrothelial Carcinoma Ureter+5 more

Estimated

~$10 – $1,050

Actual pay is set by the research site.

UroGen Pharma Ltd.NCT05874921